Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Investment Securities: 2020-2023

Historic Gains from Investment Securities for Relay Therapeutics (RLAY) over the last 1 years, with Dec 2023 value amounting to $12.4 million.

  • Relay Therapeutics' Gains from Investment Securities was N/A to $12.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $12.4 million, marking a year-over-year change of. This contributed to the annual value of $101,000 for FY2024, which is 99.18% down from last year.
  • As of Q4 2023, Relay Therapeutics' Gains from Investment Securities stood at $12.4 million, which was up 719.12% from $1.5 million recorded in Q3 2023.
  • Over the past 5 years, Relay Therapeutics' Gains from Investment Securities peaked at $30.4 million during Q4 2021, and registered a low of -$4.6 million during Q1 2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $1.5 million (2023), whereas its average is $7.1 million.
  • Data for Relay Therapeutics' Gains from Investment Securities shows a peak YoY spiked of 294.96% (in 2021) over the last 5 years.
  • Relay Therapeutics' Gains from Investment Securities (Quarterly) stood at $7.7 million in 2020, then soared by 294.96% to $30.4 million in 2021, then reached -$4.6 million in 2022, then soared by 132.92% to $12.4 million in 2023.
  • Its Gains from Investment Securities was $12.4 million in Q4 2023, compared to $1.5 million in Q3 2023 and $1.5 million in Q2 2023.